维普中文期刊产品整合服务
6篇 您的检索式:作者名="CUI Hengmi"
    题名 作者 年代 出处 被引量
1Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer显示文摘Hengmi Cui 2007Dis Markers2007,23,12:1
2Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer显示文摘Hengmi Cui 2007Dis Markers2007,23,12:1
3Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer显示文摘Hengmi Cui 2007Disease Markers2007,23,:1
4Loss of imprinting in normal tissue of colorectal cancer patients with microsatelliteinstability 显示文摘CUI Hengmi HORON I L OHLSSON R 1998Nature Medicine1998,4,11:1
5Loss of imprinting of IGF2 as an epigenetic marker for the risk o] human cancer显示文摘Hengmi Cui 2007Dis Markers2007,23,12:1
6Gene expression profile analysis reveals the effect of metformin treatment on HepG2 cells显示文摘Metformin is a first-line drug in the fight against type 2 diabetes.In recent years,studies have shown that metformin has some preventive and therapeutic effects on liver cancer,but the effects of metformin on the gene expression of liver cancer cells are not fully known.This study focused on the differences in the gene expression profiles in liver cancer cells treated with or without metformin.A total of 153 differentially expressed genes(DEGs)(FC>2 and q-values<0.001)were found,including 77 upregulated genes and 76 downregulated genes.These DEGs are involved in mitogen-activated protein kinase(MAPK),nuclear factor-kappa B(NF-κB),cell adhesion molecules(CAMs),and leukocyte transendothelial migration signaling pathways.These findings reveal the effects of metformin treatment on gene expression profiles in liver cancer cells and provide new clues for unveiling the mechanism of the antitumor effects of metformin.YI HUANG CHUNFENG DOU XUMING HU HENGMI CUI 2022BIOCELL2022,46,4:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费